Is TDOC a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Integrated Care and chronic-condition management, with revenue (fy2025) at ~$2,530 million, down ~2% from ~$2,570 million in 2024. The bear case rests on revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. Analysts covering it are spread from $5.00 to $11.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $5.00, -46.3% from the $9.31 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Integrated Care and chronic-condition management. Integrated Care is Teladoc's enterprise backbone, bundling general medical visits, mental-health access, and chronic-care programs for diabetes and hypertension carried over from Livongo. The most optimistic analyst target on TDOC is $11.00, +18.2% from the $9.31 price. That figure is only reachable if this thesis works close to its best case.

Revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth. BetterHelp faces intense competition for therapy customers and rising acquisition costs that have compressed its profitability, and the insurance pivot is unproven at scale. Teladoc still reports GAAP net losses (a net loss of roughly ~$64 million in Q1 2026) and carries debt, so the equity depends on cash flow and margin execution. Telehealth is crowded, with enterprise rivals, consumer-subscription players, and health plans building their own virtual care. The most pessimistic published target is $5.00, -46.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Teladoc Health makes money through two reporting segments.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Integrated Care and chronic-condition management) stalling in the reported numbers rather than in the narrative, the risk above (revenue has been roughly flat to declining for several years, and total revenue fell about ~2% in 2025, so the turnaround is about stabilization rather than growth) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Teladoc Health is the largest US virtual-care company. It provides telehealth visits, chronic-condition management for diabetes and hypertension, expert medical opinions, and licensable platform tools through its Integrated Care segment, sold mainly to employers and health plans, and it owns BetterHelp, a direct-to-consumer online therapy and mental-health subscription brand.

Teladoc surged during the pandemic, then fell more than 90% from its 2021 highs as telehealth demand normalized. The biggest blow was its roughly ~$18.5 billion Livongo acquisition, which it wrote down with about ~$13.4 billion of non-cash goodwill impairments in 2022, producing a historic net loss near ~$13.7 billion. Slowing growth compounded the decline.

That depends on your goals, time horizon, and risk tolerance, and this is not advice. The bull case is a cash-generative turnaround at a low valuation with a recovering BetterHelp insurance channel. The bear case is years of flat-to-declining revenue, no GAAP profit, and stiff competition. Reasonable investors weigh both differently.